Company news

Kymera Therapeutics, Inc. news in 2026

Kymera Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial

October 29, 2026

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

October 28, 2026

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

October 22, 2026

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

September 1, 2026

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

August 5, 2026

Kymera International Appoints Willson Ropp as Chief Executive Officer

July 29, 2026

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

July 28, 2026

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

July 27, 2026

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

July 7, 2026

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

June 23, 2026

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

June 12, 2026

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

June 8, 2026

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

June 8, 2026

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

May 26, 2026

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

May 15, 2026

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week

May 5, 2026

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

April 30, 2026

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

April 23, 2026

Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate

April 8, 2026

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

March 27, 2026

Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting

March 9, 2026

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

February 25, 2026

Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

February 19, 2026

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

February 3, 2026

Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

January 28, 2026

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

January 12, 2026

Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

January 6, 2026

Calls in 2026

Decks in 2026